Hercules, CA — October 8, 2012 — Bio-Rad Laboratories, Inc. today announced the launch of its semi-automated PX1 PCR plate sealer and heat seals for fast and consistent microplate sealing. Designed for PCR, real-time PCR (qPCR), and Droplet Digital™ PCR (ddPCR™) applications, the PX1 PCR plate sealer and associated heat sealing films and foils remove human variability from plate sealing and prevent sample evaporation from impacting results.
Poorly sealed microplates can permit sample evaporation, leading to large standard deviations in the number of quantification cycles (Cq) in qPCR experiments. The semi-automated design of the PX1 PCR plate sealer eliminates cumbersome manual sealing using heat and pressure to efficiently seal PCR plates, ensuring a perfect seal for uniform, reproducible PCR data.
The PX1 PCR plate sealer integrates with many different PCR workflows including Bio-Rad’s QX100™ Droplet Digital™ PCR system, providing researchers with a complete, user-friendly workflow for ddPCR. The PX1 sealer is also ideal for researchers using small sample volumes, with which evaporation is a crucial concern.
“Multiplex linearity tests in plates sealed with the PX1 sealer demonstrated amplification efficiencies in the range of 90 to 105 percent,” said Jennifer Reed, PX1 product manager in Bio-Rad’s Gene Expression division. “Efficiencies within this range are a hallmark of optimized, reliable PCR results.”
Additional benefits of the PX1 PCR plate sealer include:
- Fast startup time — ready to seal in under 3 minutes, much faster than other plate sealers that take up to 20 minutes, avoiding unnecessary delays in experiments
- Intuitive touch screen user interface — 12 programmable sealing protocols save valuable time
- Small footprint — compact design accommodates crowded benchspaces
For further details about the PX1 PCR plate sealer, please visit http://bit.ly/PX1_Sealer.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,100 people globally and had revenues exceeding $2 billion in 2011. For more information, visit www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.